Retatrutide Is Making Headlines
As excitement grows around what may become the next evolution in metabolic weight loss therapy, BioVitality is closely following the latest developments.
Once FDA approved and commercially available, BioVitality plans to offer Retatrutide as part of our medically supervised weight loss programs.
The future of metabolic medicine is evolving — and we’re committed to bringing the latest advancements to our Austin community.
Clinical trials show retatrutide, Eli Lilly’s new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the improvement of other conditions in longer studies. | Fox News
What are GLP-3s? Meet the new generation of weight-loss drugs with three key ingredients | Fox News
